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Objective. To examine alteration of serum interleukin-6 and its clinical signiﬁcance in burning mouth syndrome (BMS) patients.
Methods.48BMSpatientsand31healthycontrolsparticipatedinthestudy.Seruminterleukin-6wasmeasuredbymeansofELISA.
Hamilton rating scale of depression (HRSD) and visual analogue scale (VAS) were used to quantitiate depressive status and pain
levels of subjects, respectively. Results. 15 (31%) patients displayed substantial depressive symptoms (HRSD  16). HRSD scores
of patients were signiﬁcantly higher than controls and positively correlated to their VAS values (P = .002). Serum interleukin-6 in
patients was much lower than controls and negatively correlated to their VAS values (P = .011). However, no signiﬁcant relations
were found between interleukin-6 and HRSD scores (P = .317). Conclusions. Serum interleukin-6 in patients with burning mouth
syndrome is decreased and negatively correlated to chronic pain. Both psychological and neuropathic disorders might act as pre-
cipitating factors in BMS etiopathogenesis.
Copyright © 2007 Qianming Chen et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
Burning mouth syndrome (BMS) is a chronic condition
characterized by intraoral burning pain in the absence of
identiﬁable clinical abnormalities, aﬀecting predominantly
middle-aged women. Multiple oral sites may be involved and
the anterior two-thirds and tip of tongue are most com-
monly aﬀected. Besides the burning sensation, a variety of
symptoms could be simultaneously present, such as xerosto-
mia, dysgeusia, and psychological dysfunction [1]. To date,
despite a large body of knowledge, BMS etiology remains
largely enigmatic and presents challenge for both researchers
and clinicians.
Neuropathic background in BMS etiopathogenesis has
been underscored recently by more evidence [2]. Abnormal
perception of intensity in the prepain range and of thermal
stimuli raised trigeminal nerve sensitivity, alterations in neu-
ronal transmission, and disturbances of the mucosal neu-
rovascular microcirculatory system have been documented
in BMS patients [3–5]. All those approve the neuropathic
view on BMS.
Intriguingly, interleukins as potential neuromodula-
tors/neurotransmitters are providing increasingly impressive
database for their roles in the nociceptive processing which
lead to neuropathic pain and/or hyperalgesia [6]. Interleu-
kin-6 (IL-6), one of the neuropoietic cytokines and attract-
ing most attentions, could play various roles in nervous sys-
temincludinggliaproliferation,neuronalsurvivalanddiﬀer-
entiation, axonal regeneration, and proinﬂammatory activi-
ties [7–9]. Considering the neuropathic basis for BMS and
the potential neurological actions of IL-6, it seems interest-
ingtoexploreassociationbetweenIL-6andBMS.Earlystud-
ies showed conﬂicting data of salivary IL-6 in BMS patients
whencomparedtothehealthycontrols[10,11];nevertheless,
how about serum IL-6 and its clinical signiﬁcance?
Therefore,inthepresentstudy,serumIL-6wasmeasured
by enzyme linked immunosorbent assay (ELISA) kits and
its relationship with clinical symptoms, such as depressive
symptoms and pain levels, was also determined in BMS pa-
tients.
2. SUBJECTS AND METHODS
2.1. Patientsandhealthycontrols
This was a case control study. Patients, meeting diagnos-
tic criteria of BMS, were recruited from the Department of
Oral Medicine, West China College of Stomatology, Sichuan
University. The including criteria were based on a chief
complaint of oral pain on the tongue. Furthermore, absence2 Mediators of Inﬂammation
of clinical signs was necessary and was veriﬁed in all cases
by two professional dentists with good interexaminer consis-
tency. Controls came from the subjects who voluntarily re-
sorted to our hospital for healthy examinations. Individuals
would be excluded if they suﬀered from other local or sys-
temicdisease,tookimmunodepressantorimmunopotentiat-
ing drugs during the previous three months. Data including
age, gender, medical history, drug history, and clinical symp-
tomswererecordedindetail.Informedconsenttoparticipate
in this study was obtained from all subjects after both verbal
and written study examinations. The protocol was submitted
and approved by our Institutional Review Board (IRB).
2.2. Clinicalassessment
Two clinical parameters, pain and psychological status, were
evaluated in subjects if appropriate. The intensity of pain
was measured by using visual analogue scale (VAS). Patients
were instructed to bisect a 10cm line from 0 (no pain) to 10
(extreme pain) at a point appropriate to quantify their pain
discomfort. Meanwhile, the 17-item Hamilton rating scale
of depression (HRSD) was used to measure depressive sta-
tus of all subjects [12]. According to the quantitative sever-
ity of depressive symptoms, patients were divided into two
s u b g r o u p s ,o n ew i t ha nH R S D 16 (BMS + D, indicat-
ing substantial depressive symptoms) and the other with an
HRSD < 16 (BMS − D) [13].
2.3. IL-6determination
Blood samples were obtained from all subjects after an
overnight fast at room temperature between 9:00am and
11:00am. By using commercially available ELISA kits (R&D
Systems, Minneapolis, USA), serum IL-6 concentrations
were determined in all samples according to the manufac-
turer’s instructions. The reproducibility of this examination
was conﬁrmed by processing all samples twice.
2.4. Statisticalanalysis
The quantitative data were going through the normal dis-
tribution test. Normal distribution data were analyzed by
means of analysis of variance (ANOVA). The qualitative data
were subject to the chi-square analysis. Spearman’s Rho cor-
relationcoeﬃcientwasusedtoanalyzetherelationshipofIL-
6 levels with VAS values and HRSD scores. Probability value
of P<. 05 (two-sided) was accepted as statistically signiﬁcant
forallstatisticaltestscarriedoutinthepresentstudybyusing
SPSS version 10.0 software (SPSS Inc., Chicago, IL, USA).
3. RESULTS
3.1. Subjectcharacteristics
A total of 79 subjects participated in this study, consisting of
48 BMS patients and 31 healthy controls. The patient group
(age range 26–80 years, mean 49 ± 12 years) comprised 39
(81.25%) females and 9 (18.75%) males, with female : male
Table 1: Serum IL-6 concentrations and VAS scores in healthy con-
trols and BMS patients subdivided into those with (BMS + D) and
without (BMS −D) an HRSD score  16.
Group HRSD IL-6 (pg/mL) VAS
Control (n = 31) 2.2 ±1.41 0 .3 ±0.5—
BMS (n = 48) 10.6 ±7.47 .4 ±1.54 .4 ±2.1
BMS −D( n = 33) 6.4 ±3.37 .5 ±1.63 .9 ±1.9
BMS+D (n = 15) 20.1 ±4.37 .1 ±1.45 .6 ±2.0
F∗(df) 39.854(1/77) 102.769(1/77) —
P∗ value .000 <. 05 .000 <. 05 —
F∗∗(df) 147.336(1/46) .367(1/46) 7.411(1/46)
P∗∗ value .000 <. 05 .548 >. 05 .009 <. 05
∗All ANVOAs, showing the diﬀerences between healthy controls
and BMS patients.
∗∗All ANVOAs, showing the diﬀerences between BMS − Da n d
BMS + D subgroups.
ratios of 4 : 1. In control group there were 25 females and 6
males, and the mean age was 49 ± 11 years ranging from 30
to 61 years. No signiﬁcant diﬀerences were found in age (P =
.897) and gender ratios (P = .947) between BMS patients
and healthy controls. Of the 48 BMS patients interviewed,
69.23% (n = 27) were postmenopausal women. Moreover,
25 (52%) patients showed oral dryness of diﬀerent degrees
and 6 (13%) patients complained of poor tastes.
T h eV A Sv a l u ea sr e c o r d e do nTable 1 was remarkably
higher (P<. 05) in BMS + D subgroup compared with
BMS−D subgroup, averaging 4.4 in the whole BMS patients.
It should be noted that 15 (31%) patients displayed substan-
tial depressive symptoms (HRSD  16) with a mean value of
20.1, while the remaining 69% (n = 33,HRSD < 16) showed
a mean of 6.4. However, HRSD scores in the healthy controls
were only 2.2 on average, which were signiﬁcantly lower than
both subgroups (P<. 05).
3.2. SerumIL-6andrelationshipwith
clinicalparameters
Table 1 presented that serum IL-6 was signiﬁcantly lower in
patient group than the control (P<. 05), whereas, no sig-
niﬁcant diﬀerence (P = .548) was observed between the two
subgroups of BMS.
Correlation analysis demonstrated that serum IL-6 in
BMS patients was negatively correlated to their VAS val-
ues (r =− .362, P = .011). Moreover, positive relation-
ship was found between HRSD and VAS scores (r = .437,
P = .002).However,serumIL-6andHRSDscoreswereinde-
pendentfromeachotherwithoutanyassociation(r =− .132,
P = .317).
4. DISCUSSION
BMS is a relatively common disease that can severely af-
fect life quality of patient. Although its etiology remains elu-
sive, depressive disorder is indicated as a precipitating factor
[14]. In agreement, our data demonstrated that 15 (31%)Qianming Chen et al. 3
patientsshowedsubstantialdepressivesymptomsandthepa-
tient with higher HRSD score tended to experience more se-
vere pain (r = .437, P = .002). Thus, the HRSD might be
useful in evaluating depressive symptoms and subsequently
guiding clinical treatment in BMS patients.
Notonlypsychologicaldistress,butalsoalterationsinthe
trigeminal nociceptive pathway at peripheral and/or central
nervous system have been broadly concerned in BMS, which
support the neuropathic basis of BMS. The lingual branch of
the mandibular division of the trigeminal nerve provides af-
ferent ﬁbers to the anterior two-thirds of the tongue, as well
as to the lingual gingiva and the ﬂoor of the mouth. BMS
patients display a decreased density of unmyelinated nerve
ﬁbers within epithelium, which shows a trend toward neg-
ative correlation with duration of pain, but not severity of
pain [2]. Similarly, in our study, serum IL-6 decreased sig-
niﬁcantly (P<. 05) in BMS patients, which negatively cor-
related with pain levels (P = .011), but not depressive sta-
tus. In other words, the lower serum IL-6 is, the more se-
vere pain BMS patient tends to experience. Our results, to-
gether with the tight relationship of IL-6 with nervous sys-
tem and neuropathic diseases [13, 15], lead to a suggestion
that IL-6 might be involved in BMS etiopathogenesis, which
meanwhile strengthens the view of neuropathic background
in BMS.
DiﬀerentoutcomesofIL-6havebeendocumentedinvar-
ious neuropathic diseases, though decreased IL-6 in the pe-
ripheral blood was found in our study. Patients with persis-
tent sciatic pain display elevated IL-6 levels in the blood [16]
and following traumatic brain injury, increased IL-6 levels
are found in the brain [17]. Otherwise, either unchanged
[10]o re l e v a t e d[ 11] salivary IL-6 levels in BMS patients
have been reported. Until now, little is known about the rea-
son for those diﬀerent changes and their functional signif-
icance. In general, IL-6 could mediate immune-response in
the nervous system in response to injury or disease, which
has been suggested to be “a double-edged sword” [18]. Thus,
IL-6 could exert either detrimental or beneﬁcial eﬀects on
the nervous system, which perhaps depend on the timing
and levels of IL-6 expression. Although the inﬂammation af-
ter spinal cord injury is traditionally regarded as being detri-
mental, when delivered intraperitoneally or subcutaneously,
exogenous IL-6 is beneﬁcial for axonal regeneration [9]a n d
improves signs and electrophysiological evidence of nerve
dysfunction associated with diabetes-related neuropathy in
streptozotocin (STZ) rats [19]. On the contrary, IL-6 deﬁ-
cient mice exhibits lower nociceptive threshold to both me-
chanical and thermal stimuli, and thus is hyperalgesia in
comparison to their wild-type controls [20]. From above,
we speculate that the neuroprotective and/or neurorepara-
tive function of IL-6 could be modulated by levels of IL-6.
Then, decreased IL-6 levels might contribute to hyperalge-
sia for its attenuated neuroprotective eﬀects, which subse-
quently provides a further nice explanation to our results.
Brieﬂy, neuroprotective eﬀects of serum IL-6 on trigeminal
nociceptive pathway through some unknown mechanisms
might be weakened for lower IL-6 concentrations, which
could aggravate hyperalgesia in BMS as another precipitat-
ing factor. Yet, this view is still let to be substantiated by fur-
ther researches, such as IL-6 alterations at local mucosal tis-
sues.
Taken together, these data highlighted the psychologi-
cal and neuropathic background of BMS. The neurotrophic
and/or neuroprotective actions of IL-6 on trigeminal no-
ciceptive pathway might be alleviated in response to de-
creased serum IL-6 levels, which subsequently contribute to
the chronic pain in BMS. Nevertheless, more proofs should
beprovidedinordertoconﬁrmandfurthercharacterizeIL-6
signaling pathway in BMS, which might shed lights to novel
diagnostic and therapeutic strategies in future.
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